CNI 1493 IN MODERATE TO SEVERE PSORIATIC PATIENTS

$0M01FY2000RRNIH

Rockefeller University, New York NY

Investigators

Linked publications & trials

Paper 38386835 Paper 33715530 Paper 33011063 Paper 29807532 Paper 28654734 Paper 26160856 Paper 25063755 Paper 24938282 Paper 24315827 Paper 23416331 Paper 23322600 Paper 22732093 Paper 22709632 Paper 22326433 Paper 21917907 Paper 21791654 Paper 21421840 Paper 21252253 Paper 21183783 Paper 21178084 Paper 20595050 Paper 19933869 Paper 19895991 Paper 19889869 Paper 19595365 Paper 19250211 Paper 19217670 Paper 18645523 Paper 18481381 Paper 18425453 Paper 18339114 Paper 18239614 Paper 18090042 Paper 18045792 Paper 17978171 Paper 17947031 Paper 17942751 Paper 17937501 Paper 17928893 Paper 17909071 Paper 17825665 Paper 17702988 Paper 17618104 Paper 17513795 Paper 17502666 Paper 17389240 Paper 17362146 Paper 17332246 Paper 17324275 Paper 17286447 Paper 17222199 Paper 17209052 Paper 17182262 Paper 17147468 Paper 17065209 Paper 17053362 Paper 17018853 Paper 16991148 Paper 16985171 Paper 16917961 Paper 16908619 Paper 16880256 Paper 16879215 Paper 16841857 Paper 16794569 Paper 16763205 Paper 16759341 Paper 16652051 Paper 16645593 Paper 16569772 Paper 16470182 Paper 16393985 Paper 16380428 Paper 16359515 Paper 16344719 Paper 16336691 Paper 16251987 Paper 16177066 Paper 16109173 Paper 16081850 Paper 15995965 Paper 15988468 Paper 15957509 Paper 15930057 Paper 15893558 Paper 15867097 Paper 15823982 Paper 15809911 Paper 15793583 Paper 15784152 Paper 15781098 Paper 15734726 Paper 15643609 Paper 15622449 Paper 15520831 Paper 15519584 Paper 15516848 Paper 15464148 Paper 15456687 Paper 15367623

Abstract

The purpose of this study is to study the safety, cellular mechanism and effectiveness of CNI-1493 in treatment of psoriasis. While the exact cause of psoriasis is unknown, it is believed to involve white blood cells called lymphocytes which become activated in the skin. It is believed that these activated cells both increase tissue replication and produce inflammation within the skin. CNI-1493 is designed to block the activation of these lymphocytes. Because the CNI-1493 targets the specific cells which are involved in the symptoms of psoriasis, it may be a therapeutic advance in treatment of the disease. The purpose of this study is to test the safety, cellular mechanism and clinical activity of CNI-1493 in patients with active, moderate to sever psoriasis vulgaris.

View original record on NIH RePORTER →